中文English
ISSN 1001-5256
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

无干扰素抗HCV方案的研究进展

李强 黄玉仙 陈良

李强, 黄玉仙, 陈良. 无干扰素抗HCV方案的研究进展[J]. 临床肝胆病杂志, 2016, 32(1): 169-173. DOI: 10.3969/j.issn.1001-5256.2016.01.037
引用本文: 李强, 黄玉仙, 陈良. 无干扰素抗HCV方案的研究进展[J]. 临床肝胆病杂志, 2016, 32(1): 169-173. DOI: 10.3969/j.issn.1001-5256.2016.01.037
Li Qiang, Huang YuXian, Chen Liang. Research progress in anti-HCV therapeutic regimens without interferon[J]. J Clin Hepatol, 2016, 32(1): 169-173. DOI: 10.3969/j.issn.1001-5256.2016.01.037
Citation: Li Qiang, Huang YuXian, Chen Liang. Research progress in anti-HCV therapeutic regimens without interferon[J]. J Clin Hepatol, 2016, 32(1): 169-173. DOI: 10.3969/j.issn.1001-5256.2016.01.037

无干扰素抗HCV方案的研究进展

DOI: 10.3969/j.issn.1001-5256.2016.01.037
详细信息
  • 中图分类号: R512.63

Research progress in anti-HCV therapeutic regimens without interferon

  • 摘要: 当前,全球约有1.5亿慢性HCV感染者,其中20%会进展为肝硬化并最终死于终末期肝病和肝癌。干扰素(IFN)长期作为慢性丙型肝炎治疗的基石,在维持持续病毒学应答以及阻止病情进展方面有重要作用,但其疗效有限、不良反应多。近年来,直接抗病毒药物(DAAs)呈现出良好的疗效,在DAAs的基础上,介绍了无IFN抗HCV方案的最新研究进展,认为随着DAAs的出现,无IFN抗HCV方案发展迅速,前景较好。

     

  • [1]WHO.Hepatitis C[EB/OL][2015-04-28].http://www.who.int/mediacentre/factsheets/fs164/en/.
    [2]WEBSTER DP,KLENERMAN P,DUSHEIKO GM.Hepatitis C[J].Lancet,2015,385(9973):1124-1135.
    [3]SHAHEEN MA,IDRESS M.Evidence-based consensus on the diagnosis,prevention and management of hepatitis C virus disease[J].World J Hepatol,2015,7(3):616-627.
    [4]COLPITTS CC,LUPBERGER J,DOERIG C,et al.Host cell kinases and the hepatitis C virus life cycle[J].Biochim Biophys Acta,2015,1854(10 Pt B):1657-1662.
    [5]SHANG L,LIN K,YIN Z.Resistance mutations against HCV protease inhibitors and antiviral drug design[J].Curr Pharm Des,2014,20(5):694-703.
    [6]BAKULIN I,PASECHNIKOV V,VARLAMICHEVA A,et al.NS3protease inhibitors for treatment of chronic hepatitis C:efficacy and safety[J].World J Hepatol,2014,6(5):326-339.
    [7]HAYES CN,CHAYAMA K.Emerging treatments for chronic hepatitis C[J].J Formos Med Assoc,2015,114(3):204-215.
    [8]KOHLER JJ,NETTLES JH,AMBLARD F,et al.Approaches to hepatitis C treatment and cure using NS5A inhibitors[J].Infect Drug Resist,2014,7:41-56.
    [9] CORTEZ KJ,KOTTILIL S.Beyond interferon:rationale and prospects for newer treatment paradigms for chronic hepatitis C[J].Ther Adv Chronic Dis,2015,6(1):4-14.
    [10]CHAYAMA K,TAKAHASHI S,TOYOTA J,et al.Dual therapy with the nonstructural protein 5A inhibitor,daclatasvir,and the nonstructural protein 3 protease inhibitor,asunaprevir,in hepatitis C virus genotype 1b-infected null responders[J].Hepatology,2012,55(3):742-748.
    [11]LOK AS,GARDINER DF,LAWITZ E,et al.Preliminary study of two antiviral agents for hepatitis C genotype 1[J].N Engl J Med,2012,366(3):216-224.
    [12]KUMADA H,SUZUKI Y,IKEDA K,et al.Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection[J].Hepatology,2014,59(6):2083-2091.
    [13]LOK AS,GARDINER DF,HEZODE C,et al.Randomized trial of daclatasvir and asunaprevir with or without Peg IFN/RBV for hepatitis C virus genotype 1 null responders[J].J Hepatol,2014,60(3):490-499.
    [14]MANNS M,POL S,JACOBSON IM,et al.All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b:a multinational,phase 3,multicohort study[J].Lancet,2014,384(9954):1597-1605.
    [15]SULKOWSKI MS,GARDINER DF,RODRIGUEZ-TORRES M,et al.Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection[J].N Engl J Med,2014,370(3):211-221.
    [16]AFDHAL N,ZEUZEM S,KWO P,et al.Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection[J].N Engl J Med,2014,370(20):1889-1898.
    [17]AFDHAL N,REDDY KR,NELSON DR,et al.Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection[J].N Engl J Med,2014,370(16):1483-1493.
    [18]KOWDLEY KV,GORDON SC,REDDY KR,et al.Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis[J].N Engl J Med,2014,370(20):1879-1888.
    [19]LAWITZ E,SULKOWSKI MS,GHALIB R,et al.Simeprevir plus sofosbuvir,with or without ribavirin,to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients:the COSMOS randomised study[J].Lancet,2014,384(9956):1756-1765.
    [20]GANE EJ,STEDMAN CA,HYLAND RH,et al.Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C[J].N Engl J Med,2013,368(1):34-44.
    [21]OSINUSI A,MEISSNER EG,LEE YJ,et al.Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics:a randomized clinical trial[J].JAMA,2013,310(8):804-811.
    [22]JACOBSON IM,GORDON SC,KOWDLEY KV,et al.Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options[J].N Engl J Med,2013,368(20):1867-1877.
    [23]ZEUZEM S,DUSHEIKO GM,SALUPERE R,et al.Sofosbuvir and ribavirin in HCV genotypes 2 and 3[J].N Engl J Med,2014,370(21):1993-2001.
    [24]CORTEZ KJ,KOTTILIL S.Beyond interferon:rationale and prospects for newer treatment paradigms for chronic hepatitis C[J].Ther Adv Chronic Dis,2015,6(1):4-14.
    [25]EVERSON GT,SIMS KD,RODRIGUEZ-TORRES M,et al.Efficacy of an interferon-and ribavirin-free regimen of daclatasvir,asunaprevir,and BMS-791325 in treatment-naive patients with HCV genotype 1 infection[J].Gastroenterology,2014,146(2):420-429.
    [26]POORDAD F,LAWITZ E,KOWDLEY KV,et al.Exploratory study of oral combination antiviral therapy for hepatitis C[J].N Engl J Med,2013,368(1):45-53.
    [27]LAWITZ E,POORDAD F,KOWDLEY KV,et al.A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals(ABT-450/r,ABT-072)and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1[J].J Hepatol,2013,59(1):18-23.
    [28]FELD JJ,KOWDLEY KV,COAKLEY E,et al.Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin[J].N Engl J Med,2014,370(17):1594-1603.
    [29]FERENCI P,BERNSTEIN D,LALEZARI J,et al.ABT-450/rombitasvir and dasabuvir with or without ribavirin for HCV[J].N Engl J Med,2014,370(21):1983-1992.
    [30]ZEUZEM S,JACOBSON IM,BAYKAL T,et al.Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin[J].N Engl J Med,2014,370(17):1604-1614.
    [31]POORDAD F,HEZODE C,TRINH R,et al.ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis[J].N Engl J Med,2014,370(21):1973-1982.
  • 加载中
计量
  • 文章访问数:  1773
  • HTML全文浏览量:  25
  • PDF下载量:  392
  • 被引次数: 0
出版历程
  • 收稿日期:  2015-04-28
  • 刊出日期:  2016-01-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回